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Abstract
Introduction
• According to the CDC, DM affects 30.3 million people in the US. Five percent of 
those cases are estimated to be Type 1 Diabetes Mellitus (T1DM), and the 
incidence of DM is steadily increasing with an estimated 1.5 million new cases of 
diabetes diagnosed in 2015 alone. 
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Discussion
• Historical studies show that an intensive insulin regimen along with strict 
monitoring of blood glucose and HgbA1C levels provide patients with less long-term 
microvascular side effects of retinopathy, neuropathy, and nephropathy, as well as 
the macrovascular side effects of cardiovascular, peripheral vascular and 
cerebrovascular disease. 
• The DCCT performed by Nathan, et al. (2013) demonstrated a drop of nearly ~2.5% in 
HgbA1C and a slowed rate of loss in C-peptide responsiveness in Beta cell 
preservation. The EDIC performed by Nathan, et al. (2013) demonstrated the need 
for earlier intervention in T1DM by showing that it can reduce severe renal 
impairment by ~50%, risk of primary CVD outcomes by 42%, and nonfatal MI or 
stroke by 58%.
• As of 2015, 9.4% of the US population had a diagnosis of Diabetes Mellitus (DM). 
Although most of the data sets studied encompass type 1 (T1) and type 2 (T2) 
DM data in all ages of patients, the focus of this project will be on T1DM.
• There are effective methods currently available for the management of T1DM 
patients. These methods include: closed-loop insulin pumps that integrate a 
continuous glucose monitor (CGM) and insulin pump into one effective system 
that calculates the needed insulin doses through complicated algorithms, CGM 
with self-blood glucose monitoring calibrations (SBGM) and insulin 
administration, and SBGM with insulin administration. 
• Literature reveals that closed-loop insulin pumps have the potential to provide 
better disease management and improved disease outcomes for those patients 
who are motivated to use them as directed and find them a desirable option.
• When patients can effectively manage their blood glucose, and practice healthy 
lifestyle and dietary choices, they can avoid unnecessary hospitalizations and 
long-term diabetic complications. This will simultaneously reduce healthcare-
related costs, increase longevity and can improve the patient’s quality of life.
•Will closed-loop insulin pumps provide better efficacy by 
monitoring glycemic control according to patient’s blood 
glucose levels and glycosylated hemoglobin levels 
(HgbA1C) and decrease the incidence of hypoglycemic 
episodes, as compared to the current standard treatment 
of insulin pump therapy in patients with T1DM?  
•What are the unique benefits of the different effective 
T1DM management methods?  
•What are the challenges of these management methods 
and how will they affect their actual use-effectiveness?
• The DCCT performed by Nathan, D. M., Bayless, M., Cleary, P., Glenuth, S., Gubitosi-
Klug, R., Lachin, J. M., ... Zinman, B. (2013)showed an improvement in the INT group 
with the following outcomes: HgbA1C - by three to six months to a level of 6.9% from 
the initial 9.1% . Microvascular – results found were consistent, significant, and clinically 
meaningful. Cardiovascular – the patient population was generally too young and 
healthy to experience major CVD events (p= 0.059) INT group with three events in 
three subjects vs. CONV with twenty-one events in nine subjects. Beta cell preservation
– INT group slowed the rate of loss of C-peptide responsiveness by ~50%. 
• Devries (2017) reports results from a randomized crossover trial comparing day-and-
night closed-loop insulin delivery with usual pump therapy (four weeks each) in 29 
adults with well controlled T1DM (HgbA1C <7.5%). A closed-loop system was used, in 
which the participant determined the amount of insulin administered before each 
meal. Participants had sensor glucose concentration in target range (3.9–10.0 mmol/L) 
65.6% (SD 8.1) of the time during usual pump therapy and 76.2% (SD 6.4) of the time 
during closed-loop delivery which showed that the closed-loop system increased the 
proportion of time when glucose concentration was in target range by 10.5 percentage 
points (95% CI 7.6–13.4; p<0.001). Compared with usual pump therapy, closed-loop 
delivery reduced mean glucose concentration by 0.4 mmol/L (0.1–0.7, p=0.0226); the 
proportion of time with glucose concentration above 10.0 mmol/L by 6.9 percentage 
points (3.5–10.2; p=0.0003) and below 3.9 mmol/L by 50% (37–59, p<0.001); and 
glycemic dispersion (ie, SD of glucose concentration) by 0.5 mmol/L (0.3–0.7, p<0.001). 
• Initial management of a T1DM patient should include basic disease education, 
demonstration of SBGM, insulin administration, how to recognize and treat a 
hypoglycemic episode, and how to measure either blood or urine ketone 
concentration. This will require a multidisciplinary team that should ideally include an 
endocrinologist, a certified nurse educator, dietitian, and possibly a mental-health 
professional to provide support if the need should arise.
• As potential future family practice providers, we must consider our patient’s lifestyle, 
education level, cognition, desire for disease control, and socioeconomic status to 
adequately make a choice for their T1DM management regimen. 
• SBGM and insulin injections are relatively inexpensive, whereas newer technology is 
initially more expensive, but provide better efficacy and ease of use and also a 
decrease in hypoglycemic events and hospitalizations. Clinicians must be mindful of 
what type of insulin delivery system that they are recommending for each patient.
• Closed-loop systems have proven themselves effective; and can lessen disease burden 
on the patient’s lifestyle.  They are appropriate to prescribe for use in patients that can 
manage them efficiently and are motivated to do so. Closed-loop systems should be 
strongly considered as a long-term management method in patients with T1DM.
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Statement of the Problem
• Current medical treatment for diabetic patients require self-blood glucose 
monitoring, this monitoring is done using self-blood glucose monitors (SBGM), 
which results in many finger sticks. 
• Insulin injections can be performed by the patient or by an insulin pump that 
must be manually programmed, which requires the patient to be proficient 
calculating insulin doses independently. There is a high potential for error 
related to insulin administration due to incorrect calibration of the glucometer 
or basic human error. 
• When patients practice good blood glucose management they can avoid 
unnecessary hospitalizations and other diabetic complications, which will 
simultaneously reduce healthcare-related costs. These choices should be based 
on scientific evidence of effectiveness, not unreliable reports and should be 
made after considering the patient’s lifestyle and its’ impact on each method’s 
particular benefits and challenges. 
• The CDC (2017) states that In 2014, a total of 7.2 million hospital discharges and 
14.2 million emergency department visits were reported with diabetes being 
listed as any kind of diagnosis among US adults aged 18 years or older. The 
total direct and indirect estimated cost of diagnosed diabetes in the US in 2012 
was $245 billion; with an average of $13,700/year/person being medical 
expenditures related to diabetes. This is around 2.3 times higher than 
expenditures for people without diabetes. It is also important to note that DM 
was the seventh leading cause of death in the US in 2015.
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Common Risk Factors for Diabetic Complications
2011-2014, US adults >18 years of age with diagnosed diabetes, [95% CI]
Smoking 15.9% were current smokers and 34.5% had quit smoking but had a history of 
smoking at least 100 cigarettes in their lifetime.
BMI 87.5% were overweight or obese, defined as a BMI of 25 or greater; 26.1% having a BMI 
of 25-30, 43.5% having a BMI of 30-40, and 17.8% with a BMI of 40 or higher.
Physical Inactivity 40.8% of adults got less than 10 minutes/week of moderate to vigorous activity in 
either work, leisure, or transportation.
Hypertension 73.6% had systolic BP of 140mmHg or higher and diastolic BP of 90mmHg or higher, or 
they were already on BP controlling medications.
High Cholesterol 58.2% over age 21 with no self-reported CV disease who were eligible for statin therapy 
and were on a lipid-lowering medication. 66.9% over age 21 with self-reported CV 
disease who were eligible for statin therapy and were on a lipid-lowering medication.
Hyperglycemia 15.6% of adults had a HgbA1C value higher than 9%.
Center for Disease Control and Prevention. (2017). The National Diabetes Statistics Report [Data file]. Retrieved 
from https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf
Insulin Pump . (2018). [Graphic illustration NIH, US Dept of Health March 5, 
2018The National Institute of Health. Retrieved from 
https://medlineplus.gov/ency/imagepages/18035.htm]. 
